Cure8 research brief
People with IBD often have sleep problems and ongoing inflammation; melatonin could help both sleep and clinical disease activity, which may improve quality of life. The review suggests potential benefit but is not definitive.
Adults with IBD (Crohn's disease or ulcerative colitis), caregivers, gastroenterologists, and researchers studying adjunctive therapies and sleep interventions in IBD.
This is a systematic review and meta-analysis of randomized trials testing melatonin supplements as an add-on therapy in people with IBD.
The pooled analysis (5 trials, 214 patients) found reduced clinical disease activity and some patient-reported improvements (sleep, quality of life); effects on blood inflammatory markers were inconsistent and fecal calprotectin improved in one trial. Melatonin was generally well tolerated in the included studies.
The report is based on the article abstract (systematic review/meta-analysis) rather than a full guideline or large definitive trial. It summarizes pooled trial data and highlights heterogeneity and the need for larger, higher-quality trials before routine use can be recommended.
Practical takeaways: melatonin shows promise as a safe adjunct for improving symptoms and sleep in IBD, but evidence is limited by small trial sizes and variable biomarker effects.
Discussing melatonin with a gastroenterology clinician is reasonable if considering adjunctive use, especially to address sleep issues, but it should not replace standard IBD therapies.
This summary is grounded in the article abstract, a systematic review and meta-analysis of small randomized trials. Heterogeneity across trials and limited sample size mean results should be interpreted cautiously. The paper calls for larger, higher-quality randomized trials to confirm efficacy and safety in broader patient groups.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Physical activity may be a modifiable factor that could improve fitness, inflammation, symptoms like fatigue, and quality of life in children with IBD. This trial will provide objective, randomized data relevant to...
A wearable sensor that reliably measures inflammation markers (CRP and calprotectin) from sweat could make inflammation monitoring less invasive and more frequent for people with IBD, potentially helping detect flares...
